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Introduction: Unlike with abdominal aortic aneurysms (AAA), women appear to have an almost comparable incidence as
men for thoracic aortic aneurysms (TAA). However, the extent to which a patient’s sex influences endograft treatment of
TAA has not been reported. The current study analyzes the influence of sex on the endovascular management of TAAs.
Methods:A total of 421 patients (265 men and 156 women) were identified as part of the TAG (W. L. Gore and Associates,
Flagstaff, Ariz) thoracic stent graft trials. Preoperative risk factors, intraoperative events, and 365-day follow-up data
were analyzed.
Results: Among 18 different preoperative risk factors evaluated, women were less likely to have prior vascular procedures
(38.9% vs 55.3%; P  .004). A trend was noted toward lower rates of coronary artery disease (41.3% vs 51.2%; P  .09)
and smoking (77.8% vs 85.6%; P  .08). Women were also more likely to be nonwhite (81.4% vs 87.9%; P  .007).
Women had a smaller mean external iliac vessel diameter (7.1 vs 9.0 mm; P < .001), resulting in 24.4% vs 6.0% conduit
use (P < .001) for device delivery. Local access site complications were significantly higher in women (14.1% vs 4.5%; P
< .001). No difference was noted between sexes in the technical success rate (device delivery and successful aneurysm
exclusion) or the major adverse event rate at 30 days (26.3% vs 20.4%; P  .18). The overall length of stay was 5.5  6.2
days for female patients vs 4.8  13.0 days (P < .001). No sex-related difference was noted in endoleak rate, aneurysm
rupture, prosthetic migration, or aneurysm diameter change at 365 days.
Conclusions:No significant differences in major outcomes were noted between men and women treated with endovascular
repair of TAA at 1 month and 1 year. Women have more vascular complications, which are associated with smaller access
vessels. A lower threshold for using conduits in women may be a more prudent approach. (J Vasc Surg 2011;54:669-76.)
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wA significant difference exists in sex-based outcomes for
most vascular procedures.1,2 Women tend to be diagnosed
with a lower frequency and have significantly higher proce-
dural morbidity and mortality.1-4 In most reports on ab-
dominal aortic aneurysms (AAA), women represent ap-
proximately 15% to 20% of the study population4-7 but
comprise a higher percentage of patients with thoracic
aortic aneurysms (TAA), approaching 40% in most stud-
ies.8,9 However, the influence of sex in patients with TAA
has not been independently or adequately addressed. Our
aim was to study sex-related differences in the treatment of
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nd procedural, 30-day, and 365-day outcomes.
ATIENTS AND METHODS
All patients treated with thoracic stent grafts as part of
he preapproval and postapproval clinical trials of the Gore
AG Device (W. L. Gore, Flagstaff, Ariz) were reviewed.
ll participating sites had Institutional Review Board ap-
roval before enrollment of study subjects. We identified
21 patients (265 men and 156 women). One-year data
ere complete and available for all study participants. The
election process involved in this study and device-sizing
riteria have previously been described.8 As part of the
tudy, the aneurysms had to be atherosclerotic and fusi-
orm, and patients had to be candidates for open surgical
epair. An emergency procedure for rupture was a study
xclusion criterion. The trial did not have an open surgical
rm during study enrollment.
All preoperative computed tomography (CT) size mea-
urements and results of follow-up CT images were avail-
ble for this analysis. A core laboratory was not used in the
3-03 and 05-02 studies, but the other TAG studies used a
ore laboratory for data analysis.
Endovascular aneurysm repair was performed with the
AG device in all patients. Postoperative imaging included
hest radiographs and CT scans at 1, 6, and 12 months and
nnually thereafter. Reinterventions and their indications
ere reviewed.
Statistical analysis was performed using SAS 9.2 soft-are (SAS Institute, Cary, NC). Categoric variables were
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September 2011670 Kasirajan et alanalyzed using the two-sided Fisher exact test, and contin-
uous variables were analyzed using the two-sidedWilcoxon
rank sum test. Long-term survival was analyzed using
Kaplan-Meier methods. Values of P  .05 were considered
significant. Vascular complications were defined as any or
all of amputation, traumatic arteriovenous fistula, embo-
lism, pseudoaneurysm, restenosis, or thrombosis. Wound
complications were defined as dehiscence, leg edema, lym-
phocele/lymph fistula, or wound infection. Bleeding com-
plication was defined as procedural bleeding, postproce-
dure bleeding, coagulopathy, or hematoma.
RESULTS
Demographics. Women who underwent thoracic
stent graft therapy were less likely to be white and had a
lower body weight and height (Table I). Eighteen different
risk factors were compared between both sexes. Women
were significantly less likely to have had a prior vascular
procedure (38.9% vs 55.3%; P  .004) and had a trend
towards less coronary artery disease (41.3% vs 51.2%; P 
.09) and smoking (77.8% vs 85.6%; P  .08). Female
patients had a lower body weight and height, but had a
comparable body mass index of 27  5.3 vs 27.5  5.3
kg/m2 for men (P  .62). All other risk factors were
comparable (Table II).
Anatomic features. Maximum aneurysm diameter
was smaller in women, although this did not reach statisti-
cal significance (60 vs 62 mm; P  .09). The maximum
proximal landing zone diameter was smaller for women (31
vs 32 mm; P  .004), as was the maximum distal landing
zone diameter (30 vs 32 mm; P  .001). Access vessels
were also significantly smaller in female patients (Table III).
Procedural events. One deployment failure (access
failure) was observed in the female group. There were no
procedurally related aneurysm ruptures. Unplanned branch
vessel occlusion was comparable, at 0.6% for women vs
1.1% for men (P  .99). Conduit (only iliac conduits were
used during this study period) use for delivery of the
thoracic stent graft was far more likely in female patients
(24.4% vs 6.0%; P .001). This resulted in a higher rate of
local vascular complications (14.1% vs 4.5%; P .001) and
Table I. Comparison of race and other demographics
Variablea Male Female P
Participants, No. 265 156
Caucasian 233 (87.9) 127 (81.4) .007
African American 15 (5.7) 24 (15.4) . . .
Asian 6 (2.3) 1 (0.6) . . .
American Indian or Alaska
native 1 (0.4) 1 (0.6) . . .
Other ethnicity 10 (3.8) 3 (1.9) . . .
Age, years 71.0  10.8 72.8  9.5 .134
Weight, kg 84.8  17.2 70.7  14.3 .001
Height, cm 175.8  7.5 162.0  8.1 .001
aCategoric data are presented as number (%) and continuous data as mean
standard deviation.in more intraprocedural bleeding (8.3% vs 3.4%; P .039). (owever, the composite end point of all major 30-day and
-year adverse event rates was comparable between the
roups (Table IV). The 30-day mortality rate was 1.3% for
omen and 1.1% for men.
The incidence of paraplegia and stroke did not differ
mong the male and female patients. Male patients had a
.8% stroke incidence at 30 days compared with 1.3%
mong female patients (P  .224). The incidence of para-
legia/paraparesis was also comparable at 30 days (men,
.6%; women, 3.2%; P  .767). The use of adjuncts for
revention or decreasing the incidence of paraplegia (ie,
pinal drain) was not collected as part of this data set.
The need for intensive care unit (ICU) admission
able II. Baseline risk factors
isk factor
Male Female
PNo. (%) No. (%)
oronary artery disease 110 (51.20) 52 (41.30) .092
ardiac arrhythmia 56 (26.00) 27 (21.40) .363
alvular heart disease 19 (8.80) 11 (8.70) .99
ongestive heart failure 24 (11.20) 14 (11.10) .99
troke 26 (12.10) 16 (12.70) .866
eripheral arterial disease 34 (15.80) 17 (13.50) .638
rior vascular intervention 119 (55.30) 49 (38.90) .004
hromboembolic event 18 (8.40) 6 (4.80) .274
neurysm symptomatic 50 (23.30) 36 (28.60) .302
raumatic aneurysms 10 (5.40) 6 (5.10) .99
ther aneurysm(s) 81 (37.70) 37 (29.40) .127
OPD 88 (40.90) 46 (36.50) .491
istory of smoking 184 (85.60) 98 (77.80) .076
enal dialysis 3 (1.40) 1 (0.80) .99
araplegia 2 (0.90) 1 (0.80) .99
epatic dysfunction 6 (2.80) 4 (3.20) .99
leeding disorder(s) 7 (3.30) 2 (1.60) 0.494
ancer 51 (23.70) 30 (23.80) .99
OPD, Chronic obstructive pulmonary disease.
able III. Differences in mean preoperative computed
omography measurements
ariable Male Female P
ax aneurysm diameter, mm 62 60 .086
neurysm length, cm 8.6 8.1 .502
ortic diameter, mm
2-cm proximal 31 30 .001
1-cm proximal 31 30 .002
Immediately proximal 32 30 .002
Maximum proximal 32 31 .004
Immediately distal 31 30 .001
1-cm distal 30 29 .001
2-cm distal 30 28 .001
Maximum distal 32 30 .001
ortic neck length, cm
Proximal 4.7 5 .378
Distal 8 6.6 .244
liac diameter, mm
Right common 12 10 .001
Left common 12 10 .001
Right external 9 7.1 .001
Left external 9 7.4 .00157.7% vs 56.8%; P  1.00) and ICU length of stay was
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Volume 54, Number 3 Kasirajan et al 671comparable at 3.5 5.5 for women vs 4.3 21.1 days for
men (P  .103), but women had a longer total length of
hospital stay (5.5  6.2 vs 4.8  13.0 days; P  .001).
Major device-related events and follow-up. The
percentage of participants experiencing any major device-
related adverse event at 365 days was 2.6% for women and
3.5% for men (P  .775). No difference in endoleak rate
was also noted at 30 and 365 days (Table V). During the
1-year follow-up period, one aneurysm rupture occurred in
the male subset, and one stent graft migration occurred in
the female subset. Aneurysm enlargement was comparable
at 365 days (Table V). Survival at 1 year was 86.7% for
women vs 90.5% for men, which was not significantly
different (P  .229; Fig). Most of the deaths during
follow-up were unrelated to the TAA or the stent graft,
with the exception of three patients: two men with aor-
toesophageal fistula and graft infection and one woman
with hemoptysis.
The specific vascular complication experienced by each
patient is provided in Table VI with the treatment that was
undertaken to correct the complication. Major bleeding
was defined in the protocol as 1 liter of blood loss which
requires transfusion or medical therapy.
Most patients experienced a decrease in the size of the
Table IV. Local and systemic complications at 30 and 365
Complication
0-30 days, No. (%
Male Female
Participants, No. 265 156
Any major adverse event 54 (20.4) 41 (26.3)
Bleeding 9 (3.4) 13 (8.3)
Pulmonary 15 (5.7) 9 (5.8)
Renal 3 (1.1) 0 (0.0)
Vascular 12 (4.5) 22 (14.1)
Cardiac 7 (2.6) 4 (2.6)
Wound 5 (1.9) 9 (5.8)
Bowel 1 (0.4) 3 (1.9)
Other 1 (0.4) 0 (0.0)
Additional implantation 0 (0.0) 0 (0.0)
Table V. Major device-related events up to 1 year
Event
0-30 days, No. (
Male Female
Participants, No. 265 156
Endoleak 10 (3.8) 3 (1.9)
Type I 6 (2.3) 2 (1.3)
Type IA 5 (1.9) 2 (1.3)
Type IB 1 (0.4) 0 (0.0)
Type II 1 (0.4) 1 (0.6)
Type III 0 (0.0) 0 (0.0)
Indeterminate 3 (1.1) 0 (0.0)
Aneurysm rupture 0 (0.0) 0 (0.0)
Prosthesis migration 0 (0.0) 0 (0.0)
Prosthesis material failure 0 (0.0) 0 (0.0)
Aneurysm enlargement 0 (0.0) 0 (0.0)aneurysm or stabilization, and only 7.9% had an increase in aneurysm diameter on long-term (60 months) follow-up
Table VII).
ISCUSSION
To our knowledge, this is the first sex-based analysis for
atients with descending TAA treated with thoracic stent
rafts. Women typically constitute a higher proportion of
he study population in TAA studies compared with AAA
tudies.8,9 Women undergoing stent graft repair of AAA
eem to have less favorable outcomes than men.10-14 Typ-
cally, women tend to have smaller access vessels and more
omplex vascular anatomy, resulting in a higher incidence
f aborted procedures, access complications, and late graft
ailure.10-14 Our study found men and women were com-
arable for major baseline risk factors such as chronic
bstructive pulmonary disease (COPD), cardiac, renal fail-
re, and age. In fact, women appeared to have a trend
oward lower systemic risk factors than men for coronary
rtery disease (41.3% vs 51.2%; P  .09) and history of
moking (77.8% vs 85.6%; P  .076).
The most striking difference between men and women
ppears to be access vessel diameters. This has been dem-
nstrated in various studies of AAA endografts and typically
esults in higher access site–related complications and
s
31-365 days, No. (%)
P Male Female P
260 151
.184 43 (16.5) 27 (17.9) .786
.039 6 (2.3) 0 (0.0) .09
.99 14 (5.4) 11 (7.3) .522
.299 6 (2.3) 3 (2.0) .99
.001 7 (2.7) 1 (0.7) .267
.99 18 (6.9) 13 (8.6) .564
.046 1 (0.4) 1 (0.7) .99
.146 2 (0.8) 2 (1.3) .627
.99 2 (0.8) 0 (0.0) .534
. . . 6 (2.3) 2 (1.3) .716
31-365 days, No. (%)
P Male Female P
260 151
0.388 5 (1.9) 3 (2.0) .99
4 (1.5) 2 (1.3)
3 (1.2) 1 (0.7)
1 (0.4) 1 (0.7)
2 (0.8) 0 (0.0)
0 (0.0) 1 (0.7)
0 (0.0) 0 (0.0)
1 (0.4) 0 (0.0) .99
0 (0.0) 1 (0.7) .367
1 (0.4) 0 (0.0) .99
2 (0.8) 1 (0.7) .99day
)%)borted procedures.5,12,15 In the event of iliac rupture, this
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September 2011672 Kasirajan et alcan result in a greater blood loss, possible death, and
prolonged ICU stay, with an increase in all associated
systemic complications. Typically, thoracic stent grafts
need a larger access vessel (9.2 mm for the largest TAG
devices) compared with 7 mm for most AAA endografts.
Despite this need for a larger access vessel, only one intent-
to-treat failure was noted in one female patient in our study.
However, women required a higher incidence of iliac con-
duits for device insertion (24.4% vs 6.0%; P .001), which
in turn resulted in a higher incidence of wound and vascular
complications (14.1% vs 4.5%; P  .001).
Overall, there were 39 planned conduits and 15 un-
planned (emergency) conduits. Unplanned conduits re-
sulted in a greater blood loss (mean 660.7 vs 427 mL) and
a higher overall incidence of major adverse events (53.3% vs
23.1%; P .05) and local vascular complications (26.7% vs
2.6%; P .018). Interestingly, the local vascular complica-
tions were more common in the femoral access route than
the elective conduit route (7.9% vs 2.6%). Hence, it appears
Fig. Survival at 1 year is shothat elective conduits generally do not result in a higher mncidence of vascular complications when performed in a
ontrolled manner.
We can hypothesize that the higher incidence of vascu-
ar complications in our study may be related to an initial
ttempt at femoral insertion and conversion to a conduit in
he event of a failure. Transfemoral failure of device inser-
ion can have a variety of failure modes, ranging from
imple failure to advance device with no arterial trauma to a
atastrophic iliac rupture. Even in patients with an atrau-
atic failure at transfemoral insertion, the procedure for
erforming an emergency conduit is more complex due to
he systemic heparin that often cannot be reversed due to
he need for femoral occlusion at the site of the attempted
evice insertion. In female patients, a great attention to
ccess vessels is mandatory in relation to diameter, calcifi-
ation, and tortuosity. It is best to perform a conduit when
n doubt.
The mean diameter of the proximal and distal landing
one of the thoracic aorta among female patients was 30
r male and female patients.m in our study. This would have required an 8.6-mm
s
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However, the mean external iliac diameter among female
patients was a little more than 7.0 mm. For the male
patients requiring the same device (based on an average
landing zone diameter of 31 mm), the mean external iliac
diameter was 9.0 mm. Despite these significant differences
Table VI. Specific vascular complication experienced by e
Treatment group Sex Study day Adverse event
TAG device
0303 F 0 Vascular trauma 9 interpo
0303 F 0 Vascular trauma
0303 F 21 Vascular trauma 14 brach
0303 F 0 Vascular trauma 12
0303 F 0 Vascular trauma 9 R ileo-
0402 F 0 Vascular trauma Interpos
0402 F 0 Vascular trauma Interpos
0502 M 212 AVF Repair o
0502 F 0 Vascular trauma Left caro
0502 M 7 Pseudoaneurysm Thromb
0502 F 0 Vascular trauma Stenting
0502 M 0 Embolism Carotid
0502 M 0 Vascular trauma Stent in
0502 M 0 Vascular trauma Femoral
0502 M 307 Embolism Endovas
0502 M 165 Thrombosis Right br
0502 M 0 Vascular trauma Conduit
0502 M 17 Pseudoaneurysm Pseudoa
0502 Fe 15 Vascular trauma
0502 M 0 Pseudoaneurysm L femor
pseud
9901 F 0 Vascular trauma Ligation
9901 F 0 Vascular trauma Right ex
9901 M 45 Pseudoaneurysm Right fe
9901 M 115 Thrombosis
9901 M 0 Embolism Right fe
9901 M 1 Embolism Right fe
9901 F 0 Vascular trauma Wallgraf
9901 F 0 Thrombosis Thromb
9901 F 0 Vascular trauma Left fem
9901 F 0 Vascular trauma 1. Right
9901 M 0 Vascular trauma Repair o
graft
9901 M 0 Vascular trauma (L) Iliac
9901 F 0 Thrombosis Right ili
9901 F 0 Vascular trauma (L) ileo-
9901 F 0 Vascular trauma (l) Com
9901 M 1 Thrombosis (1) Fem
9901 M 97 Pseudoaneurysm Surgical
9901 M 94 Vascular trauma Repair o
9901 M 0 Embolism L femor
9901 M 0 Vascular trauma L comm
9901 Fe 127 Thrombosis (1) Iliac
9901 M 7 Thrombosis
9901 M 7 Thrombosis
9901 F 0 Vascular trauma Ilio-fem
9901 F 0 Vascular trauma Left fem
9901 F 0 Thrombosis Left fem
9901 F 0 Vascular trauma Vessel st
9901 F 0 Vascular trauma Left fem
9901 F 0 Embolism Embolec
9901 F 0 Thrombosis Femoral
F 1 Vascular trauma Surgery
AAA, Abdominal aortic aneurysm; AVF, arteriovenous fistula; F, female; Min the challenges related to the access vessels, we noted no cignificant difference in relation to the major adverse
vents, stroke, and paraplegia. This may be related to
xperience of the operators and the low threshold for
erforming a conduit.
Although beyond the scope of this article, women had
lower body weight and height than men, but had a very
atient
Surgery or procedure
n graft bypass
tery patch angioplasty
ypass
common iliac to common femoral artery; Dacron bypass graft
common iliac to common femoral artery; Dacron bypass graft
t femoral AVF
ubclavian bypass
ection/US-guided thrombin injection
ht iliac artery
lectomy/arteriogram
common iliac
rterectomy
exclusion for thromboembolic disease of infrarenal AAA
l embolectomy with vein patch angioplasty
sm repair
ess site developed pseudoaneurysm; thrombin injected into
rysm using US guidance
ght common and external iliac; left axillobifemoral graft
l iliac tear repaired with a graft
l pseudoaneurysm repair w/J-P drain
p bypass
p bypass
t
y left femoral artery
rtery interposition graft placement
fem bypass graft; 2. Iliac vein repair with sutures
tured (R) external iliac artery, insertion (R) ilio-fem interposition
placement
bypass graft
ypass graft
femoral artery interposition graft
crossover graft; (2) thrombectomy of superficial fem & profunda
r with tube graft
with aortobiiliac bypass graft
ry thrombectomy endarterectomy and patch
xternal iliac wall graft
bectomy; (2) R fem-fem crossover
ss (right)
rtery end-end reconstruction, (l) external, iliac stent
ndarterectomy left common iliac stent placement
(intraoperative)
ndarterectomy and patch angioplasty, embolectomy
R to L fem-fem bypass graft
y patch
; US, ultrasound.ach p
sitio
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September 2011674 Kasirajan et alP  .09). Hence, using the same aneurysm size criteria for
repair of TAA may not be acceptable. Various authors have
advised the use of an aortic size index that requires the use
of the body surface area in relation to the maximum diam-
eter of the aneurysm.16 The body surface area in turn is
calculated using the height and weight as part of the
Dubois-Dubois formula.16 They noted that at every age
and body surface area, women’s aortas were smaller.
Hence, they argued that an aneurysm of the same size may
represent more advanced disease in a woman compared
with a man, and that reliance on diameter as the primary
indication for surgery has resulted in referral for surgery at
a later stage of disease amongwomen. The use of bodymass
index as comparison to aneurysm size is not reliable because
body mass index is more a reflection of body fat than the
actual diameters of the vasculature.
Other authors have also looked for a variety of other
possible contributing factors, including changes in the ac-
tivity of inflammatory mediators in the presence of higher
estrogen levels and increased proximal thoracic aortic stiff-
ness in elderly women that may account for an overall poor
outcome for female patients with aneurysms.17,18 How-
ever, our study showed that the results in women are
comparable with men in all major study end points using
the TAG device.
Various endograft studies on AAA have reported a
higher endoleak rate for women. In the European Collab-
orators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) registry, women had a 1.7 times
higher endoleak rate than men.19
The endoleak rates in our study at 30 and 365 days
were comparable for both subsets. It is possible, due to the
longer landing zones seen in this study (5 to 8 cm), that the
endoleak rate may be an under-representation compared
with population-based studies. No ruptures occurred in the
female patients at 1 year compared with one rupture in a
male patient. Aneurysm enlargement was 1% in both
subsets at 1 year.
Despite being the largest reported series on women
receiving thoracic stent grafts, the present study is limited
to the confines of well-controlled prospective studies. The
results are only applicable to the TAG graft and may not be
generalizable to patients undergoing repair with other
types of endograft. Patients at high anatomic or physiologic
risks or those who were not candidates for open surgical
repair could not be treated as part of the TAG studies. As a
result, it is possible that a significant number of female
Table VII. Change in aneurysm diameter from baseline
Change 6 12
5-mm decrease in diameter 29 (32.2) 64 (45.7)
5-mm change in diameter 55 (61.1) 70 (50.0)
5-mm increase in diameter 6 (6.7) 6 (4.3)patients with poor vascular anatomy or other systemic riskactors might have been eliminated. This may explain why
he women and men in this study had similar outcomes
ompared with those in most population-based studies, in
hich women tend to fare worse than men for most vascu-
ar interventions.20 Unfortunately, data on patients treated
t the study sites not included in the study were not
vailable for this analysis.
In addition, industry-sponsored studies for device ap-
roval are typically conducted in high-volume, experienced
enters. However, because a large portion of the overall
rocedural volumes are performed in low-volume centers
ith limited experience, outcomes in such patient popula-
ions may not directly reflect those from well-controlled,
rospective clinical studies.
ONCLUSIONS
There was no significant difference in major study end
oints between male and female patients. The TAG device
as equally successful in aneurysm exclusion at 1 year in
oth men and women. The smaller access vessels in female
atients require a lower threshold for performance of elec-
ive conduits. Future device development, in addition to
ocusing on features such as conformability and placement
ccuracy, needs to pay greater attention to lower-profile
horacic devices to better suit the female patient popula-
ion.
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Dr Peter Schneider (Honolulu, Hawaii). Dr Kasirajan pres-
ents a subanalysis of the data of the Gore TAG registry of endo-
vascular repair with descending thoracic aortic aneurysms. This is
one of the largest databases currently available comprising more
than 400 patients, and the focus is the effect of gender on the
perioperative, 1-month, and 1-year outcomes of thoracic endovas-
cular aneurysm repair (TEVAR).
The results of TEVAR largely improve with time, with device
modifications and better selection of patients. I would be interested to
learnmore about fromwhichGore TAGdevice trial were the patients
recruited, and the time period of this study. Since the Pivotal study
there have been several modifications to the device design in removal
of the spine wire, the incorporation of a low permeability layer, and
the introduction of the 45-mm device. Any of these device modifica-
tions could have had an effect on the overall outcome.
I am a little surprised to see only 1-year data was analyzed. In
2008, Dr Makaroun already reported 5-year results of TAG com-
pared with open repair patients. Since device complications, espe-
cially migration can occur later, it remains unclear whether the lack
of difference in overall success between genders can be maintained
in the long-term.
A higher incidence of access-related complications and
conduit use in women is to be expected and well known. What
is important is to learn to avoid these complications. As the
authors admitted, patient selection will determine the outcome.
I had an opportunity recently to review a similar manuscript for
the JVS based on a gender analysis from the Medtronic Vascular
Talent Thoracic Stent Graft System for the Treatment of Tho-
racic Aortic Aneurysms (VALOR) registry. They reported a
vessel disruption rate of 21% in women despite a conduit being
used in 39%, and an overall vascular complication rate of 36%.
The average vessel diameter in their series for women was onlyhile the overall primary end point at 1 year was significantly
etter for women, mainly due to a higher incidence of aneurysm
xpansion in men, with no difference in migration and endoleak
ates between gender.
The author has to be congratulated on the excellent results of
ery low endoleak rates and zero rupture at 1 year. However, there
s no information on aneurysm expansion, which had been previ-
usly reported to occur in as much as 19% in the earlier studies.
erhaps these would have an impact on aneurysm-relatedmortality
n the longer-term.
I have the following questions for the author. First, does
our database comprise all patients in the TAG registry since
999, or did all these patients receive the current version of the
tent graft?
Dr Karthikeshwar Kasirajan. A total of 140 subjects were
ncluded from TAG 99-01 who received the original device design
ith the longitudinal spine wire, and this was published with the
-year data. TAG 03-03 had 51 patients with the longitudinal
pine removed. TAG 04-01 had 80 patients and was part of the
ontinued access study until Food and Drug Approval (FDA)
pproval. TAG 05-02 had 150 patients and was the postmarket
urveillance study. No 45-mm devices were used in any of the
tudies included in this analysis. At the time of analysis the TAG
5-02 had just completed the 1-year follow-up. Hence, data
nalysis was done for the 1-year end point.
Dr Schneider. Question 2: Can you elaborate on the “bleed-
ng complications” in women and whether they are related to a
maller vessel size, or with the use of large sheaths. Did you
ompare the size of the access vessels and the delivery system to
etermine if there is a relationship between vascular injury and the
egree of mismatch, and whether there is a predilection towards
mplantation in men with larger diameter grafts?Dr Kasirajan. Typically male patients had a larger diameter for the
xternal iliac and had a lower incidence of access complications. Sheath
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September 2011676 Kasirajan et alsize did not correlate with access vessels as the smallest access vessels had
conduits and typically had larger access sheaths placed via these conduits
for possible device oversizing. Bleeding complications were associated
with need for emergency conduits and not necessarily related to elective
conduits or femoral access.Dr Kasirajan. No differences were noted based on actual
neurysm diameter between genders. However, women had a
maller proximal and distal landing zone. This may suggest that
omen had larger aneurysms compared to males if correlated with
he proximal or distal aortic diameters. Hence, some authors haveDr Schneider. Is there any difference in the outcome of the aneu-
rysm sac, given that the starting size of the two genders was similar?
suggested that women should have a lower threshold for treatment
based on aneurysm diameter.
